Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Actinic Keratosis (AK)
Interventions: 5-FU Cream, Efudex®, Vehicle; Drug
Lead sponsor: Sol-Gel Technologies, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cerritos, California

Conditions: Rheumatoid Arthritis
Interventions: Sarilumab, Etanercept, Methotrexate, Placebo (for sarilumab), Placebo (for etanercept), Adalimumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 776 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 30
States / cities: Birmingham, Alabama • Glendale, California • Thousand Oaks, California + 27 more

Conditions: Sexual Arousal Disorder
Interventions: Placebo, SST-6007; Drug
Lead sponsor: Strategic Science & Technologies, LLC; Industry
Eligibility: 21 Years to 60 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Postoperative Pain
Interventions: EXPAREL and Local Anesthetics, Oral Opioid and Local Anesthetics; Procedure
Lead sponsor: Bellaire Facial Surgery Center; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Atlanta, Georgia • Houston, Texas • The Woodlands, Texas

Conditions: Self-Compassion, Self-care, Self-care Agency, Self-kindness, Self-valuation
Interventions: Kindness-focused, Health-focused; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 21 Years and older
Enrollment: 177 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Stanford, California

Conditions: Lupus Nephritis
Interventions: Anifrolumab, Placebo; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 17
States / cities: Glendale, Arizona • Phoenix, Arizona • La Jolla, California + 13 more

Conditions: Skin Diseases
Interventions: Diphenylcyclopropenone (DPCP); Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Substance Abuse
Interventions: Strengthening Families Program Online eLearning Game, SFP Home-use DVD, Wait-Listed Control; Behavioral
Lead sponsor: Strengthening Families Program LLC; Industry
Eligibility: 11 Years and older
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Dementia
Interventions: palmar grasp without dorsal stimulation, standard palmar grasp test with dorsal stimulation; Other
Lead sponsor: Rowan University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Stratford, New Jersey

Conditions: Cerebrospinal Fluid Leak
Interventions: FS VH S/D 500 s-apr, DuraSeal Dural Sealant; Drug · Device
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 10
States / cities: Springfield, Illinois • Springfield, Massachusetts • Detroit, Michigan + 7 more

Conditions: Type1 Diabetes Mellitus
Interventions: HDV insulin lispro 100 UNIT/mL, Insulin Lispro 100 Units/mL; Drug
Lead sponsor: Diasome Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Immunization, Vaccination
Interventions: STOP-HPV bundle intervention; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 11 Years to 17 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Itasca, Illinois

Conditions: Osteogenesis Imperfecta
Interventions: Bisphosphonate, Setrusumab; Drug · Biological
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 2 Years to 6 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 10 more

Conditions: Heart Failure
Interventions: Atrial support pacing through cardiac resynchronization therapy. Device: RENEWAL family of CRT-D devices; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,742 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostatic Neoplasms
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Matching placebo (normal saline), Abiraterone, Prednisone/Prednisolone; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 806 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 29
States / cities: Anchorage, Alaska • Tucson, Arizona • Oceanside, California + 25 more

Conditions: Acute Pain, Surgery
Interventions: NeuroIDgenetix Test Panel; Other
Lead sponsor: AltheaDx; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy Volunteers
Interventions: CC-11050; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Sleep Apnea, Obstructive
Interventions: Seltorexant 40 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 4
States / cities: Atlanta, Georgia • New York, New York • Cincinnati, Ohio + 1 more

Conditions: Contraception
Interventions: Interaction with users of IUC and non-IUC users, Interaction with non-IUC users only; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 630 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Skin Wrinkling
Interventions: Emervel Classic Lidocaine, Juvederm® Ultra; Device
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 8 more

Conditions: Knowledge, Behavior
Interventions: STEPS2, STYH; Behavioral
Lead sponsor: City University of New York, School of Public Health; Other
Eligibility: 16 Years to 27 Years
Enrollment: 856 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Racism, Healthcare Disparities, Minority Health
Interventions: Non-verbal communication score; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Down Syndrome
Interventions: Exercise; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes Mellitus, Type 2, Hyperuricemia
Interventions: Low-fructose diet, isocaloric, Allopurinol, Placebo, Low-fructose, hypocaloric; Other · Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 40 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Columbia, Missouri

Search by objective public record fields.

Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

Study to Evaluate the Efficacy and Safety of SST-6007, a Topical Sildenafil Cream, Compared to Placebo in Women With Female Sexual Arousal Disorder

Efficacy of EXPAREL in Comparison to Standard of Care for the Treatment of Post Operative Dental Implant Pain

Comparison of Two Nutrition-Based Interventions on Physician Well-being

Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis

Trem-1 and Ultraviolet Radiation-induced Immune Suppression

Strengthening Families Program Online

Hand Grasping Techniques on Eliciting the Grasp Reflex in Patients With Dementia

Efficacy and Safety of FS VH S/D 500 S-apr (Tisseel) as an Adjunct to Sutured Dural Repair in Cranial Surgery

21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus

The STOP-HPV Trial 4: Bundle Intervention

Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta

PEGASUS CRT Study: Atrial Support Study in Cardiac Resynchronization Therapy

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms

Prospective Observational Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Patients Undergoing Elective Surgical Procedures

A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole

A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea

Online Peer Influence on IUD Behaviors and Attitudes

Emervel Classic Lidocaine Versus Juvederm® Ultra in Treatment of Moderate to Severe Facial Wrinkles and Folds

Socialization To Enrich Participation & Support Sexuality for Young People With I/DD

Assessing Patient-provider Interactions During the Preoperative Anesthesia Consult

Blood Flow and Blood Pressure Investigation in Down Syndrome

Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid